Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares

Atara Biotherapeutics' director Brian N. Cherry recently acquired nearly $1 million worth of the company's common stock. On September 4, 2026, Cherry purchased 104,166 shares at a price of $9.6 per share, totaling around $999,993. The stock is currently trading at $9.76, marked by an 81% increase over the past six months. InvestingPro analysis suggests that the stock may be overvalued, given its market capitalization of $95.66 million.

Following this acquisition, Cherry now directly owns 166,486 shares of Atara Biotherapeutics common stock. The transactions were facilitated through Atara Biotherapeutics' sales agent, TD Securities (USA) LLC, under a Sales Agreement signed on November 1, 2023.

In related news, Atara Biotherapeutics has announced a change in its board of directors. Carol Gallagher, who served on the board for 13 years, is stepping down. Cherry has been appointed as a new director, as reported in a company press release. President and CEO Cokey Nguyen expressed gratitude for Gallagher's commitment to the company and its shareholders, highlighting the significance of this change in the company's governance as it pursues its strategic objectives.